Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Atopic Dermatitis
JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis
March 7th, 2008
JADO Technologies GmbH, the leading developer of RAFT intervention therapeutics, announced positive results from a Phase IIa clinical trial of its lead RAFT modulator TF002 in patients with severe atopic dermatitis. TF002, a topical formulation of miltefosine, exerts its anti- inflammatory activity via RAFT modulation. RAFTS are sub-compartments in the lipid membrane of cells that play a role in the complex physiological processes, such as immune response. The randomised, double-blind, active (hydrocortisone) controlled, 17 patient study demonstrated that TF002 met its primary endpoint of significant reduction of inflammation in atopic skin. The anti-inflammatory effect...
Source: Health Business Week (2008-03-07)
|
